Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?

Kidney International

Volumn 63, Issue 1, 2003, Pages 298-305

  Zeier, Martin ^a,b,c,d,e   Schwenger, Vedat ^b,c,d,e   Deppisch, Reinhold ^b,c,d,e   Haug, Ulrike ^b,c,d,e   Weigel, Kai ^b,c,d,e   Bahner, U ^b,c,d,e   Wanner, Christoph ^b,c,d,e   Schneider, H ^b,c,d,e   Henle, Thomas ^b,c,d,e   Ritz, Eberhard ^b,c,d,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Gambro Corporate Research   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Nephrology Center   (Germany)

Author keywords

Advanced glycation end products; Carbonyl compounds; Glucose degradation products; Oxidative stress; Peritoneal dialysis

Indexed keywords

3 DEOXYGLUCOSONE; 4 DIDEOXYGLUCOSON 3 ENE; ACETALDEHYDE; BUFFER; CARBOHYDRATE DERIVATIVE; CARBOXYMETHYLLYSINE; GLUCOSE DEGRADATION PRODUCT; HUMAN SERUM ALBUMIN; LYSINE DERIVATIVE; PERITONEAL DIALYSIS FLUID; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; FEMALE; FLUORESCENCE; HUMAN; IN VIVO STUDY; INSTRUMENT STERILIZATION; MALE; OXIDATION; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC CIRCULATION; TIME;

EID: 0037213451     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00705.x     Document Type: Article

References (25)

1. Martinson E, Wieslander A, Kjellstrand P, Boberg U: Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose. ASAIO J 38:M370-M372, 1992
2. Wieslander A, Andrén A, Martinson E, et al: Toxicity of effluent peritoneal dialysis fluid. Adv Perit Dial 9:31-35, 1993
3. Maillard LC: Action des amides aminés sur les sucres. Formation des mélanoides par voi méthodique. C R Acad Sci Ser 145:66-68, 1912
4. Henle T, Deppisch R, Beck W, et al: Advanced glycated end-products (AGE) during haemodialysis treatment: Discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 14:1968-1975, 1999
5. Wieslander A, forsbäck G, Svensson E, et al: Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluids. Adv Perit Dial 12:57-60, 1996
6. Lindën T, Forsbäck G, Deppisch R, et al: 3-deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 18:290-293, 1998
7. Cappelli G, Bandiani G, Cancarini GC, et al: Low concentrations of glucose degradation products and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag. Adv Perit Dial 15:238-242, 1999
8. Rippe B, Simonsen O, Heimbürger O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348-357, 2001
9. Koomen GDM, Betjes MGH, Zemel D, et al: Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int 14:132-136, 1994
10. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, et al: Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 10:64-69, 1995
11. Nilsson-Thorell CB, Muscalu N, Andrén A, et al: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 13:208-213, 1993
12. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
13. Pocock SJ: The Analysis and Interpretation of Crossover Trials, in Clinical Trials, Chichester, John Wiley & Sons, 1983, pp 114-119
14. Kislinger T, Fu C, Huber B, et al: N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749, 1999
15. Hylander B, Granroth B, Wieslander A: CA 125 during the first 8 weeks of CAPD treatment: Influence of GDP. Perit Dial Int 21(Suppl 1):27, 2001
16. Miyata T, Horie K, Ueda Y, et al: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425-435, 2000
17. Koschinsky T, He CJ, Mitsuhashi T, et al: Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94:6474-6479, 1997
18. De Vriese AS, Tilton RG, Stephan CC, Lameire NH: Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12:1734-1741, 2001
19. Inagi R, Miyata T, Yamamoto T, et al: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 463:260-264, 1999
20. De Vriese AS, Mortier S, Lameire NH: Glucotoxicity of the peritoneal membrane: The case for VEGF. Nephrol Dial Transplant 16:2299-2303, 2001
21. Miyata T, Sugiyama S, Saito A, Kurokawa K: Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int 59(Suppl 78): S25-S31, 2001
22. Miyata T, Devuyst O, Kurokawa K, Van Ypersele De Strihou C: Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61: 375-386, 2002
23. Witowski J, Wisniewska J, Korybalska K, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 12:2434-2441, 2001
24. Jones S, Holmes CJ, Krediet RT, et al: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 59:1529-1538, 2001
25. Wieslander AP: Cytotoxicity of peritoneal dialysis fluids - is it related to glucose breakdown products? Nephrol Dial Transplant 11:958-959, 1996